RSNA 2024 Spotlight: Careverse Leads the New Trend in Medical AI
CHICAGO, Dec. 12, 2024 /PRNewswire/ -- From December 1st to 5th, 2024, RSNA 2024—the largest and most future-oriented top medical event in the global radiology community, was held in Chicago. At this conference, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its innovative achievements in multimodal imaging AI and large language models with medical experts...
2024 Design Intelligence Award Held at China Academy of Art, Hangzhou, China
HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The ceremony for the 2024 Design Intelligence Award (DIA) took place on December 6 at the Liangzhu Campus of China Academy of Art (CAA). The Fourier General-Purpose Humanoid Robot GR-1 clinched the Grand Award, the highest prize of DIA. Gold Awards were presented to several remarkable projects, including the THETA Dental Implant...
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion
Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® devices in Asia Transaction highlights R-Bridge's commitment to supporting access to innovative, high-quality, and safe healthcare solutions SINGAPORE, Dec. 12, 2024 /PRNewswire/ -- R-Bridge...
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY® (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. It is also the first prescription issued for VELSIPITY®...
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
LOS ANGELES, Dec. 12, 2024 /PRNewswire/ -- Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The presentation will feature preclinical characterization of LAE118, a novel allosteric pan-mutant selective PI3Kα inhibitor. "We appreciate this recognition of our expertise and strength in...
QNET Stands in Solidarity with Cambodia and the World for a Mine-Free Future
HONG KONG, Dec. 12, 2024 /PRNewswire/ -- QNET, a global leader in direct selling and lifestyle products, proudly sponsored the recently concluded 'March for a Mine-Free World' in Siem Reap, Cambodia. This impactful event, hosted in collaboration with the Cambodian Mine Action and Victim Assistance Authority (CMAA), showcased Cambodia's unwavering commitment to becoming mine-free by 2025. March...
THERME GROUP ACQUIRES THERME ERDING AND SECURES €320 MILLION FINANCING, TO CREATE THE WORLD’S LARGEST WELLBEING INFRASTRUCTURE PLATFORM
The Acquisition of Europe's Largest Wellbeing Destination, Backed by One of the Industry's Largest Single-Asset Financings LONDON, Dec. 12, 2024 /PRNewswire/ -- Therme Group announces the acquisition of Therme Erding, the largest wellbeing destination globally located near Munich in Germany. With this transaction, Therme Group is set to surpass 3.5 million annual...
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial protocols confirmed and initiated with leading global stroke research centers * SEOUL, South Korea, Dec. 11, 2024 /PRNewswire/ -- GNT Pharma Co. Ltd, a...
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42. From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules were synthesized and screened. Preclinical studies demonstrate ISM5411 to be gut-restricted and PHD-specific, thus reducing cardiovascular and systematical tumorigenic risks. Two...
Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results
BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and nine months ended September 30, 2024. Financial and Operational Highlights for the Third Quarter of 2024 Marked improvement in...
